What we do

Vitalograph manufactures and supplies high quality spirometers and other respiratory diagnostic devices. Our products aid the detection, diagnosis and management of respiratory conditions and are used by medical professionals in healthcare and occupational health settings worldwide.

We have also supported many successful clinical trials with respiratory endpoint solutions and project services, working with some of the world’s leading pharmaceutical companies, biotechs and contract research organisations.

Who we are

Vitalograph is a global provider of medical devices and clinical drug trials services, with sites in Ireland, the UK, the USA, Germany, and Japan. Our mission is to improve patient lives through supporting our customers and partners by designing and providing market-leading respiratory diagnostic products and services.

Company Name Vitalograph (Ireland) Ltd.

Address Gort Road Industrial Estate, Ennis, Co. Clare.

Website www.vitalograph.com/ie/

Green Service Provider Antaris Consulting Ltd.


In a world that is rapidly changing, having a clear and evolving ESG strategy means we remain relevant, responsive, agile, and influential. It allows us to grow a resilient business, and to proudly contribute to the industry we operate in, as well as the communities we live in.

GreenStart Project Objectives

1) Develop a high-level sustainability strategy for Vitalograph

2) Develop an evidence-based benchmark of Vitalograph’s current sustainability performance.

3) Agree on an internal governance structure and sustainability reporting rhythm that will enable Vitalograph to progress with confidence on its sustainability journey

Key Challenges

While our approach to business and manufacturing operations is generally well intentioned to minimise our environmental impact, we currently have an ad hoc approach to reducing our environmental impact and no monitoring or system for measuring our performance against targets. The challenge is to embed sustainability into our strategy, culture and systems.

– Objective diagnostic tools are used in fewer than half of diagnoses for common conditions such as asthma and COPD in he EU and USA and far less in LMIC, leading to inaccurate diagnosis or underdiagnoses. This tends toward either wasteful overprescription of medication (on a “try it and see if it helps” basis) or at the other end of the spectrum lack of treatment or delays in finding effective treatment with impact on patient quality of life. A growth challenge is to include consideration of ways to improve access to quality respiratory diagnostic testing.


As an outcome of this project, the sustainability priorities for Vitalograph are clear and we will be able to start operationalising and reporting against targets in 2023, embedding sustainability in our strategy to 2026 and taking action to reduce our carbon emissions.